| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1 |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) |
| 04 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
$75 million funded upfront with an additional $325 million tied to milestones, providing |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Intellia Therapeutics, Inc. (the "Company") held its Annual Meeting to consider and vote on the three proposals set forth below, each of which is described in detail in the Proxy Statement. The following is a summary of ... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 |
| 30 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
1. Introductory. Intellia Therapeutics, Inc., a Delaware corporation (“Company”), agrees with Jefferies LLC (“Jefferies”), Goldman Sachs & Co. LLC (“Goldman Sachs”) and Citigroup Global Markets Inc. (“Citi” and together with Jefferies an... |
| 27 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Phase 3 HAELO Clinical Trial: Topline Data for Lonvo-z April 27, 2026 |
| 10 Apr 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or ... |
| 02 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
CAMBRIDGE, Mass., March 2, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027 |
| 27 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
INTELLIA THERAPEUTICS Corporate Overview January 2026 Exhibit 99.1 |
| 10 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-z |
| 29 Oct 2025 |
8-K: Other Events
On October 29, 2025, the United States Food and Drug Administration (the “FDA”) verbally informed the Company that the FDA has placed a clinical hold on the Investigational New Drug applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 ... |
| 27 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
CAMBRIDGE, Mass., Oct. 27, 2025 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily ... |
| 25 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three years |
Loading...